Raymond James Financial’s Pacific Biosciences PACB Stock Holding History

Raymond James Financial’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Sell	159,749 -4,809	-3%	-$6.99K	﹤0.01%	4885
2026 Q1	$217K	Sell	164,558 -18,720	-10%	-$33.5K	﹤0.01%	4847
2025 Q4	$343K	Buy	183,278 +21,413	+13%	+$41.1K	﹤0.01%	4489
2025 Q3	$207K	Buy	161,865 +9,896	+7%	+$13.4K	﹤0.01%	4605
2025 Q2	$188K	Buy	151,969 +21,863	+17%	+$25.2K	﹤0.01%	4546
2025 Q1	$154K	Sell	130,106 -8,010	-6%	-$12.3K	﹤0.01%	4478
2024 Q4	$253K	Buy	+138,116	New	+$270K	﹤0.01%	4281

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raymond James Financial's PACB Position: Q2 2026 in Review

Raymond James Financial reduced its Pacific Biosciences (PACB) stake by 2.9% in Q2 2026, selling an estimated $6.99K and leaving 159,749 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #4885.

Raymond James Financial first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $343K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Raymond James Financial held 159,749 shares of Pacific Biosciences worth $268K as of Q2 2026.
Raymond James Financial sold 4,809 Pacific Biosciences shares in Q2 2026, an estimated $6.99K.
Pacific Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4885 holding.
Raymond James Financial first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Pacific Biosciences position peaked at $343K in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.